Sividon Diagnostics develops breast cancer prognostic tests. Sividon's core EndoPredict product is a kit-based RNA expression test designed to assess the aggressiveness of breast cancer on a molecular level through the evaluation of 12 genes.
Phone: +49 221 669 561 00
|Investor||Investor Type||Location||Participating Rounds|
|Title||Application Date||Patent Date||Status
(Patent / Application)
|Method for predicting the response to chemotherapy in a patient suffering from or at risk of developing recurrent breast cancer||Sep 23, 2016||Application|
|Method for breast cancer recurrence prediction under endocrine treatment||Aug 11, 2016||Application|
|Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer||Jan 31, 2014||Application|